EoPancreas: New Diabetes Patch Pump and CGM System in Development
$ 12.00 · 4.9 (663) · In stock
FDA has granted "Breakthrough Device Designation" to South Korean company EoFlow, developing a tubeless patch-pump based Automated Insulin Delivery (AID) system.
FDA has granted Breakthrough Device Designation to South Korean company EoFlow, developing a tubeless patch-pump based Automated Insulin Delivery (AID) system.
The Future of Closed-Loop Systemsㅤ
The Future of Closed-Loop Systems
8 Great CGM and Insulin Pump Patches for People with Diabetes
Insulet, Abbott earn EU nod for artificial pancreas system
Diabetes Management with Insulin Pumps and CGMs (Continuous Glucose Monitors)
Comparison of Automated Insulin Delivery Systems
Diabetes Café (@Diabetesto) / X
Device updates JDC monthly diabetes newsletter. Issue 126 April 2019.
Quarterly Update Diabetes Technology
Insulin Delivery Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update
Quarterly Update Diabetes Technology